The Associated Press: Gadgets to Go Green at Electronics Show Photo 1 of 3 Gadgets to Go Green at Electronics Show By PETER SVENSSON – 6 days ago Consumer electronics aren't exactly easy on the environment — they consume electricity that contributes to global warming, and toxins leach out of them when they end up in landfills. But the industry that's inviting us to get
Advantag of ingestion administration way is its easiness even when applied at home. But with their help necessary treatment concentration in blood cannot be always quickly achieve buy antibiotics online transaction is carried out on anonymity and mutual profit principles, and in addition customers will be positively surprised with quality and speed of service.
Lifeak.bien-etre-quotidien.frLIFEWAVE ® IN-PROGRESS STUDIES
Double-blind, placebo controlled study to determine the efficacy of the LifeWave Energy
Patch in improving fitness, strength, endurance and balance in 30 healthy humans.
The assessments will include stretch and reach, lat pull downs, hand strength and various
measures of performance on a stationary ergometer bicycle. The tests chosen for this study were
based on results from a pilot study. They were chosen for the results they presented and to be
conducted in a short enough time to insure proper compliance and performance from subjects.
Effects of Lifewave Energy Patches on Acupuncture Meridians & Biophoton Emission in
Human Subjects This expanded study is based on the findings of an earlier pilot study
conducted in 2009. The statistical analyses of “before-after” changes indicated that the Energy
Enhancer Patches, when applied at KI-1 points, influence the body’s energetic conditions
including the following observations:
• Reduction of bio-photon emission implying enhanced coherence of cell activities • Bio-energy shift to lower half of the body • Enhancement of immune system activity In order to re-confirm these observations under scientifically more vigorous conditions a “genuine tvs placebo” double-blind test is proposed with 30 trials in 15 subjects as requested by Lifewave earlier his year. The subjects will be tested in a double-blind manner in a cross-over study. Doppler Laser Perfusion Imaging and Saliva Testing on the Energy Enhancer Patches 20
healthy subjects are being recruited to participate in this double-blind, placebo controlled Using
the Periscan Imager to look at micro vascular perfusion pre and post application of the Life
Wave Energy Enhancer patches. The Periscan Imager uses a low energy laser beam (wavelength
670nm, max. output 1mW, beam diameter 1mm) that interacts with red blood cells flowing
through cutaneous blood vessels resulting in a frequency change of the laser beam that is
dependent on the red cell velocity. The measurement is passive and there are no known risks to
this measurement process. An image of the fingers is produced showing color-coded areas of low
to high blood flow.
All subjects will also undergo saliva testing with the following panels: Cortosol, DHEA-sulfate, Estradiol, Progesterone, Testestosterone, Salivary Chloride, Salivary Potassium, Salivary Sodium. The questionnaires will include Tellegen Absorption Scale, Global Mood Scale, Hassels and Uplift Scale, Arizona Integrative Outcomes Scale Visual Analogue self assessment for energy. IceWave®
Infrared Thermal Imaging in Determining Effectiveness of IceWave Patches This open-
label, 100-person placebo-controlled clinical study of the IceWave pain patches has two main
goals: To determine the effectiveness of pain control of the IceWave patches compared to
placebo after 48 hours and to evaluate the clinical effect of the patches on mental acuity, bowel
function and daily activities, as reported on a 10-point Likert scale. Infrared images will be taken
prior to patch placement as a secondary method for validating the Likert Scale assessment.
Subjective randomized, two center, placebo-controlled study to test efficacy of non-
transdermal pain patch A two-center, 200 person pain study is in progress with subjects
experiencing arthritic pain. Subjects at each site will be divided into two treatment groups
receiving either the placebo or active pain patch. Over a seven-day period subjects will be
recording their pain intensity in a pain diary which includes a pain scale and evaluating pain
levels before and after patch application. Conclusions will be drawn on the effectiveness of the
pain patches when compared to placebo in treating the symptoms of pain.
Open-label Pain Study Comparing the Effects of the IceWave Pain Patches to the Regular
Treatment of Various Pain Medications A 40-person, single-center pain study focused on
elderly subjects on a regular regimen of pain medication. This study will divide subjects into two
treatment groups: one where the subjects will use only the IceWave patches to treat their pain
symptoms and the second where subjects will continue on their pain medications. Both groups of
subjects will cross-over into the other group after a 5-day period and be continuously evaluated
using a mixture of infrared imaging to diagnose the source of pain; pain scales to quantify the
level of pain experienced at intervals; and functional scale to evaluate the impact of the pain on
routine daily activities. The study will be open-label and no placebos will be used. Comparisons
will be drawn at the end of the treatment periods to evaluate the effects and effectiveness of both
treatments on treating the symptoms of pain.
Pilot Study on Chronic Pain and the Body’s Biochemical Response. A 10-person pilot study
is in progress at an Italian center for health and well-being. The study will focus on subjects
exhibiting chronic pain and their biochemical response, as measured by the BioExplorer. The
Bioexplorer method has been devised to provide an instrumental, non-invasive assessment of
active biochemical processes occurring both in the cerebrospinal areas and in the inner organs of
the human body. This will be combined with regular self-assessments on pain intervals.
Open-label Study to Determine the Effects of the IceWave Pain Patches on Controlling
Pain A 40-person, two-center pain study focused on subjects experiencing pain. Subjects will
use only the IceWave patches to treat their pain symptoms for a 5-day period and be monitored
daily to access their impact on managing the pain and for any adverse events. The study will be
open-label and no placebos will be used. Comparisons between baseline pain levels and 5 day pain levels will be accessed using a Visual Analogue Scale for pain. Silent Nights®
Double-blind, placebo controlled study to measure subjective and objective effects of Silent
Nights patch on sleep quality. A double-blind placebo controlled study to determine the Silent
Nights patch on individuals with varying degrees of sleep difficulties. Subjects will be evaluated
using both objective and subjective measures. Nightly sleep activity will be recorded using an
actigraphy device and cellular physiological organ status will be assessed routinely. A sleep log
and a standardized questionnaire focused on evaluating sleep quality will also be used in
conjunction with both devices.
Pilot Study to Test Effectiveness of Silent Nights on Improving Sleep in Subjects Suffering
from Chronic Obstructive Pulmonary Disease (COPD) A 10 person pilot group will measure
the effects of Silent Nights on improving quality of sleep in subjects suffering from COPD. A
higher prevalence of insomnia has been found in those with COPD versus the general
population. Sleep quality will be measured by several validated sleep questionnaires and indexes.
The study outcomes will be used to inform a larger study in the near future.
Pilot Study Measuring Oxidative Stress and Inflammation Panel Testing on Tissue Samples
from Subjects Using Y-Age Aeon Samples from eight subjects with varying health histories
were taken at different intervals over a period of time to access the impact of Y-Age Aeon on
inflammation and oxidative stress and antioxidant reserves and overall health.
X-15 [Y-Age Aeon] Focus Group Study A world-wide focus group study led by over 80
healthcare practitioners familiar with Lifewave patches and proper applications testing the
effects of Aeon over a 60-day period. Subjects are asked to track their progress weekly by rating
their impact on several objective measures and comparing it to baseline levels.
Reducing Mental Decline Due to Glycosylation and Oxidative Stress Single A single-study
site conducting a double-blind placebo controlled study on the effects of the Carnosine patches
on restoring mental decline and cellular damage due to aging. Improvements in mental cognition
will be measured using eeg and standardized tests. Secondary goals of the study are to show that
the Carnosine patches stimulate acupuncture points effectively and safely and if skin
conductance increases after patch application. This will be evaluated by measuring heart rate
variability and skin conduction activity. These two measurements will verify that the patch is
actively affecting the bioelectrical system of the body.
A double-blind, placebo controlled study with 20 subjects is currently testing the effects of the Y-Age Glutathione patch on mental focus. Mental focus will be assessed using a series of standardized questionnaires. A secondary goal will be to test for meridian stimulation, which will be evaluated using Gas Discharge Visualization (GDV). Y-Age® System (Carnosine, Glutathione, and Aeon)
Effects of Y-Age on varied skin types A three-month study in Australia is being conducted
using all three Y-Age products together: Carnosine, Glutathione and X15 to evaluate their effects
on a variety of skin types. A smaller group will be using placebo patches and those results will
be compared with the larger group using the active patches. Dermatologist-grade cameras will be
used to photograph the subjects on a weekly basis to track the progress on oil secretion, keratin
layers, moisture levels and pigmentation.
POR FAVOR LEA ESTOS TÉRMINOS Y CONDICIONES CON CUIDADO. Estos Términos y Condiciones (el “Acuerdo”) establecen los términos legalmente vinculantes para usar el sitio de Internet http://www.comedycentral.la (“Sitio”, “nosotros”, “nos”, y “nuestro”) en coordinación con el canal Comedy Central Latinoamérica (“Canal Comedy Central”) ambos operados por MTV Networks Lati